Last reviewed · How we verify
Imatinib escalation
At a glance
| Generic name | Imatinib escalation |
|---|---|
| Sponsor | Shanghai Zhongshan Hospital |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Diarrhoea
- Headache
- Cough
- Abdominal pain
- Vomiting
- Pain in extremity
- Nasopharyngitis
- Nausea
- Fatigue
- Rash
- Arthralgia
- Pyrexia
Key clinical trials
- Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate (PHASE1)
- Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency (PHASE1)
- A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) (PHASE1)
- A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101) (PHASE1)
- MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST) (PHASE1, PHASE2)
- First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (PHASE1)
- A Study to Try to Bring Back Radioiodine Sensitivity in Patients With Advanced Thyroid Cancer. (PHASE1)
- De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in Chronic Myeloid Leukaemia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Imatinib escalation CI brief — competitive landscape report
- Imatinib escalation updates RSS · CI watch RSS
- Shanghai Zhongshan Hospital portfolio CI